What Is Liraglutide?

1. What Is Liraglutide?

Liraglutide is an active ingredient used in prescription GLP-1 receptor agonist medicines. The current DailyMed Victoza label and DailyMed Saxenda label both identify their products as liraglutide injections and as glucagon-like peptide-1 (GLP-1) receptor agonists.

The word “liraglutide” identifies the active ingredient. It does not, by itself, tell you whether someone is talking about Victoza, Saxenda, a generic product, a diabetes treatment, or a weight-management treatment.

The terminology breaks down as follows:

2. Why Liraglutide Matters in GLP-1 History

Today, public discussions about GLP-1s are often shaped by newer products, leading many to associate the category exclusively with weekly injections or oral tablets. Liraglutide serves as a reminder that the category includes older, once-daily formulations.

For broader background, see What Is a GLP-1?. “GLP-1 receptor agonist” is a class phrase that encompasses several different active ingredients, labels, routes of administration, and brand names. Liraglutide distinctly illustrates the brand-versus-molecule difference: “Victoza” and “Saxenda” are not just alternative names for liraglutide, but rather different brand contexts with specific label framing and indications.

3. How Is Liraglutide Related to Victoza?

Victoza is a brand name for a specific liraglutide product. The current DailyMed Victoza label describes it as a GLP-1 receptor agonist indicated for glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes mellitus. It also includes cardiovascular-risk language for defined adults with type 2 diabetes and established cardiovascular disease.

FDA’s liraglutide marketed as Victoza information page places Victoza firmly in the type 2 diabetes context. In a December 23, 2024 announcement, the FDA described the approval of the first generic referencing Victoza, also in a type 2 diabetes context.

4. How Is Liraglutide Related to Saxenda?

Saxenda is another brand name for a liraglutide product. The current DailyMed Saxenda label describes it as a GLP-1 receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in defined adult and pediatric populations.

While both Victoza and Saxenda are once-daily liraglutide injections, their brand names point to different regulatory label contexts and approved uses.

5. Why Once-Daily Wording Gets Attention

Because newer GLP-1 discussions often center on weekly injections or oral tablets, liraglutide’s once-daily dosing stands out. Current Victoza and Saxenda labels describe them as once-daily subcutaneous injections, which differs from once-weekly products such as Ozempic, Wegovy, Trulicity, Mounjaro, and Zepbound.

This frequency difference highlights that GLP-1 receptor agonists vary significantly by active ingredient, brand, route, and labeled dosage schedule. “GLP-1 shots” are not universally weekly; liraglutide is the primary daily counterexample.

For semaglutide-specific context, see What Is Semaglutide?. For brand-specific semaglutide explainers, see What Is Ozempic? and What Is Wegovy?.

6. Liraglutide, Semaglutide, Dulaglutide, and Tirzepatide

Liraglutide, semaglutide, dulaglutide, and tirzepatide are distinct active ingredients. Current labels describe liraglutide, semaglutide, and dulaglutide products as GLP-1 receptor agonists. Tirzepatide is described as both a GIP receptor and GLP-1 receptor agonist.

Active ingredient names (like liraglutide and semaglutide) are distinct from brand names (like Victoza and Ozempic) and drug classes (like GLP-1 receptor agonists).

7. Generic Liraglutide Context

On December 23, 2024, the FDA announced the approval of the first generic referencing Victoza (liraglutide injection, 18 mg/3 mL) for type 2 diabetes.

This generic approval applies specifically to the Victoza reference product, not Saxenda. Availability, pharmacy substitution, and insurance coverage for generic liraglutide depend on specific prescriptions, brand references, and local pharmacy regulations.

8. What Is Liraglutide FAQ

• What is liraglutide in simple terms?

  Liraglutide is an active ingredient used in prescription GLP-1 receptor agonist medicines. In the U.S., it is the active ingredient in Victoza (for type 2 diabetes) and Saxenda (for chronic weight management).

• Is liraglutide the same as Victoza or Saxenda?

  No. Liraglutide is the active ingredient. Victoza and Saxenda are brand names for specific liraglutide products with different approved uses.

• Is liraglutide a daily or weekly GLP-1 medicine?

  Current Victoza and Saxenda labels describe once-daily subcutaneous injection products. That frequency makes liraglutide different from once-weekly GLP-1 products such as semaglutide and dulaglutide injections.

• How is liraglutide different from semaglutide, dulaglutide, or tirzepatide?

  They are different active ingredients. Liraglutide is associated with Victoza and Saxenda, semaglutide with Ozempic and Wegovy, dulaglutide with Trulicity, and tirzepatide with Mounjaro and Zepbound. Tirzepatide is also classified as a combined GIP/GLP-1 receptor agonist.

9. Sources